Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00392912 · ClinicalTrials.gov registry record · NA
Effect of Testosterone Therapy in Men With Alzheimer's Disease and Low Testosterone
A NA study, sponsored by Michael E. DeBakey VA Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT00392912 is a NA study that has completed, run by Michael E. DeBakey VA Medical Center. The registered enrollment target is 10 participants.
The verdict
NCT00392912, a NA study, has completed, sponsored by Michael E. DeBakey VA Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
Treatment with testosterone can improve performance on tests of spatial ability in men with low testosterone levels and Alzheimer's disease. Improved performance on these tests may mean an improved ability to get around in one's environment without getting lost or injured. This could have a positive impact on both patients and those who care for them. We will investigate what areas of the brain are involved in these improvements in spatial ability. This will be done using a PET scan, which creates a 3-dimensional image of the brain that can allow us to see how the brain functions.
Interventions
- DRUG AndroGel (Solvay Pharmaceuticals)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2007-04 |
| Est. Completion | 2010-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00392912
The ClinicalTrials.gov registry entry for NCT00392912 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Michael E. DeBakey VA Medical Center, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AndroGel (Solvay Pharmaceuticals) is the first listed.
NCT00392912 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00392912 about?
NCT00392912 is a clinical study titled "Effect of Testosterone Therapy in Men With Alzheimer's Disease and Low Testosterone". Treatment with testosterone can improve performance on tests of spatial ability in men with low testosterone levels and Alzheimer's disease. Improved performance on these tests may mean an improved ability to get around in one's environment without getting lost or injured. This could have a positive...
What is the current status of trial NCT00392912?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2007-04. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00392912?
The interventions under investigation include: AndroGel (Solvay Pharmaceuticals) (DRUG).
Who is sponsoring clinical trial NCT00392912?
This trial is sponsored by Michael E. DeBakey VA Medical Center, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.